EPHA2 and neoplasm: Rao and colleagues reported that inhibition of HSP90 resulted in proteasome-dependent degradation of its client oncoprotein EphA2 and, hence, increased tumor recognition by EphA2-specific CD8+T lymphocytes (168, 169).